This section focuses on two H2O2-based cancer therapeutic modalities, pharmacological ascorbate (gram doses delivered intravenously reaching plasma concentrations ≥ 20 mM; P-AscH−), and superoxide dismutase (SOD) mimetics, in the context of the balanced duality of these agents to potentially protect non-malignant tissues from therapy-induced toxicities. Here, SOD1 is linked to cancer.